Katherine Stueland Sells 23,108 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 23,108 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84. Following the completion of the transaction, the chief executive officer now directly owns 82,318 shares of the company’s stock, valued at $5,801,772.64. This represents a 21.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.
• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total transaction of $121,287.87.

GeneDx Trading Down 2.3 %

Shares of NASDAQ:WGS opened at $69.38 on Thursday. GeneDx Holdings Corp. has a 12-month low of $1.29 and a 12-month high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm has a fifty day moving average of $58.11 and a two-hundred day moving average of $38.91.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.82) earnings per share. Equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

WGS has been the subject of a number of recent research reports. BTIG Research upped their price objective on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, TD Cowen raised their price target on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $59.33.

Institutional Investors Weigh In On GeneDx

Hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in GeneDx during the second quarter worth about $34,000. nVerses Capital LLC bought a new stake in shares of GeneDx in the 2nd quarter worth approximately $50,000. CWM LLC acquired a new stake in shares of GeneDx during the 3rd quarter worth approximately $89,000. SG Americas Securities LLC bought a new stake in shares of GeneDx during the third quarter valued at approximately $198,000. Finally, Point72 DIFC Ltd acquired a new position in shares of GeneDx in the third quarter valued at $220,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.